Gefapixant, sold under the brand name Lyfnua, is a medication used to treat chronic (long-term) cough. It acts as an antagonist of the P2RX3 receptor.
It was authorized for medical use in the European Union in September 2023.
Gefapixant is indicated for the treatment of refractory or unexplained chronic cough.
It was named in honour of Geoff Burnstock.